Navigation Links
ENCO Pharmaceutical Development Announces Another Successful FDA Inspection - Its 2nd This Year
Date:3/20/2013

JACKSONVILLE, Fla., March 20, 2013 /PRNewswire-iReach/ --  ENCO Pharmaceutical Development's Jacksonville, FL Facility Completes Successful FDA Audit

ENCO Pharmaceutical Development, Inc. (EPDI) is pleased to announce the completion of a successful FDA inspection of its Jacksonville FL facility.  The audit was a directed Pre-approval Inspection (PAI). 

The audit occurred between March 7th and 8th, 2013.  Upon the completion of the inspection, the investigator reported no findings and no Form 483 was issued.

"As a company we understand the value of maintaining a high level of compliance," said Mark Inman , Ph.D., VP and Director of Quality Assurance.  "Not only do we want to ensure adherence to the existing regulatory requirements, EPDI also remains connected to the various regulatory bodies we work with to keep the company at the forefront of changes in the regulatory industry."

This audit marks the second consecutive month that an EPDI facility has been audited by the FDA.  In February, auditors inspected EPDI's Cary, NC facility.  "Between the two audits, our company has experienced nearly 5 days of intensive inspection by the FDA with no 483's or observations to report," Mark Inman continued. 

The audit covered thorough reviews of general systems such as training, equipment calibration/qualification, SOP's, protocols and methods and involved a variety of technical areas including analytical development and release testing.

ENCO Pharmaceutical Development Inc. provides a broad spectrum of pharmaceutical development and analytical services from its facilities in Jacksonville, FL and Cary, NC.  The company works with a variety of organizations in both the pharmaceutical and medical device industries, including global, small and mid-size firms, as well as virtual organizations. EPDI provides expertise in formulation development of solid, semi-solid, liquids, ophthalmic and lyophilized dosage forms as well as analytical support for method development and validation, stability studies, raw materials testing, extractable/leachable studies, medical device testing and more. For additional information, please visit www.encopharma.com.

Media Contact: Keith Hurley , ENCO Pharmaceutical Development, Inc., 336.541.3270, khurley@encopharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ENCO Pharmaceutical Development, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST ) ... and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a ... sales at constant currency (organic) grew by 3.9%. ... to $0.60 in the prior-year quarter. Second-quarter 2017 adjusted ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... “Vinaya” Rednam distinguishes herself once more by being among Houston’s first plastic surgeons ... the highest quality plastic surgery care without disrupting busy schedules and maintaining the ...
(Date:8/17/2017)... ... August 17, 2017 , ... Florida Hospital Zephyrhills showcased ... community partners. The newly renovated ER was designed with patients in mind and ... semi-private rooms to deliver patient results, improve efficiencies and reduce length of stay, ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, new features, ... changes to the smartwatch market. As of June 2017, nearly nine percent of U.S. ... months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast from NPD’s ...
(Date:8/17/2017)... ... 17, 2017 , ... Pot Valet is a leading provider of premium medical-grade ... the state, and soon, every state in the country, the company offers patients safe, ... dispensary altogether. , According to Pot Valet, all California patients have the ...
(Date:8/17/2017)... VA (PRWEB) , ... August 17, 2017 , ... ... for Great Employers , an international competition, were announced today. The awards recognize ... products and suppliers who help to create and drive great places to work. ...
Breaking Medicine News(10 mins):